[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-342692-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-342692-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","preclinical-advances-in-lnp-crispr-therapeutics-for-solid-tumor-treatment-review","Preclinical Advances in LNP-CRISPR Therapeutics for Solid Tumor Treatment - Review","","Solid tumors present long-standing therapeutic challenges due to complex cellular architecture and genetic heterogeneity. CRISPR genome editing offers precise genetic intervention, yet progress from bench to bedside depends heavily on efficient delivery of CRISPR components into tumor cells. Lipid nanoparticles (LNPs) provide a biocompatible delivery platform by encapsulating the CRISPR/Cas9 system, supporting targeted delivery while reducing off-target risks. Preclinical findings report disruption of oncogenic pathways and tumor regression, suggesting strong translational potential. Continued research and clinical testing are necessary, but combined CRISPR/Cas9 and LNP strategies indicate promising future personalized cancer therapy.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/preclinical-advances-in-lnp-crispr-therapeutics-for-solid-tumor-treatment-review/342692/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/preclinical-advances-in-lnp-crispr-therapeutics-for-solid-tumor-treatment-review/342692.png","ImageObject",300,407,{"name":42,"@type":43},"Ava Thompson","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why is efficient delivery of CRISPR components a key hurdle for treating solid tumors?","Question",{"text":63,"@type":64},"The document highlights that success depends on delivering CRISPR components efficiently into tumor cells and tissues. Delivery limitations restrict the full therapeutic potential of CRISPR technology.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How do lipid nanoparticles (LNPs) support CRISPR/Cas9 therapeutic delivery?",{"text":68,"@type":64},"LNPs can encapsulate the CRISPR/Cas9 system, enabling targeted delivery. They are described as biocompatible and tunable, helping improve delivery efficiency while mitigating off-target effects.",{"name":70,"@type":61,"acceptedAnswer":71},"What preclinical outcomes are associated with LNP-mediated CRISPR delivery in solid tumors?",{"text":72,"@type":64},"Pre-clinical investigations reported efficacy of LNP-mediated CRISPR delivery, including disruption of oncogenic pathways and subsequent tumor regression.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},342692,1790127749,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":55,"slug":125},"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},1649267921044,"https://us-avatar.wpscdn.com/avatar/1800007509477c92dfb?_k=1786009248482753345","cells  \nReview  \nPreclinical Advances in LNP-CRISPR Therapeutics for Solid Tumor Treatment  \nShuting Wang 1, Yuxi Zhu 2, Shi Du 3,4,* and Yunsi Zheng 1, *  \nCitation: Wang, S.; Zhu, Y.; Du, S.; Zheng, Y. Preclinical Advances in LNP-CRISPR Therapeutics for Solid Tumor Treatment. Cells 2024, 13, 568 . [https://doi.org/10.3390/](https://doi.org/10.3390/)[ ](https://doi.org/10.3390/)cells13070568  \nAcademic Editors: Paola Ulivi, Giorgia Marisi and Milena Urbini  \nReceived: 27 January 2024  \nRevised: 10 March 2024  \nAccepted: 22 March 2024  \nPublished: 24 March 2024  \nCopyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \n1 School of Pharmacy, Hainan Medical University, Haikou 571199, China; [hy0207113@hainmc.edu.cn](hy0207113@hainmc.edu.cn)  \n[2](2 Department of Pediatrics)[ Department of Pediatrics](2 Department of Pediatrics), [University Hospitals Rainbow Babies & Children](University Hospitals Rainbow Babies & Children)’[s Hospital](s Hospital), [Cleveland](Cleveland), [OH 44106](OH 44106), USA; [yuxi.zhu@uhhospitals.org](yuxi.zhu@uhhospitals.org)  \n3 Division of Pharmaceutics and Pharmacology, College of Pharmacy, The Ohio State University, Columbus, OH 43210, USA  \n4 Department of Biomedical Informatics, College of Medicine, The Ohio State University, Columbus, OH 43210, USA  \n* Correspondence: [du18@osumc.edu](du18@osumc.edu) (S.D.); [hy0207125@hainmc.edu.cn](hy0207125@hainmc.edu.cn) (Y.Z.)  \nAbstract: Solid tumors, with their intricate cellular architecture and genetic heterogeneity, have long posed therapeutic challenges. The advent of the CRISPR genome editing system offers a promising, precise genetic intervention. However, the journey from bench to bedside is fraught with hurdles, chief among them being the efficient delivery of CRISPR components to tumor cells. Lipid nanoparticles (LNPs) have emerged as a potential solution. This biocompatible nanomaterial can encapsulate the CRISPR/Cas9 system, ensuring targeted delivery while mitigating off-target effects. Pre-clinical investigations underscore the efficacy of LNP-mediated CRISPR delivery, with marked disruption of oncogenic pathways and subsequent tumor regression. Overall, CRISPR/Cas9 technology, when combined with LNPs, presents a groundbreaking approach to cancer therapy, offering precision, efficacy, and potential solutions to current limitations. While further research and clinical testing are required, the future of personalized cancer treatment based on CRISPR/Cas9 holds immense promise.  \nKeywords: lipid nanoparticles (LNPs); CRISPR; solid tumors; genome editing; translational research  \n1. Introduction  \nIn recent years, the integration of clustered regularly interspaced short palindromic repeats (CRISPR) technology with lipid nanoparticle (LNP) delivery systems emerged as a novel anti-cancer strategy. This innovative approach combines the precision of the CRISPR system for gene editing with the efficacy of LNPs in targeting solid tumors, offering a promising avenue for personalized cancer treatment.  \nThe CRISPR system, originally a powerful gene-editing tool, has found wide-ranging applications in cellular gene editing, gene expression regulation, and the creation of gene knockout animal models [1] . Furthermore, it has been used in cancer therapeutics by enabling the editing of multiple genes, thereby offering innovative solutions for inhibiting tumor growth and enhancing our understanding of cancer mechanisms. As we delve deeper into the intricacies of tumor biology, the role of the CRISPR system in unraveling the genetic underpinnings of various cancers becomes increasingly apparent [2] . This technology has begun to be applied in the treatment of vari","cbCaivNvgiaysVXM","https://ap.wps.com/l/cbCaivNvgiaysVXM","pdf",1268045,14,"English","# Introduction\n## Limitations of CRISPR and delivery challenges\n# LNPs as delivery carriers for CRISPR/Cas9\n## Targeting strategies and clinical translation considerations\n# Pre-clinical progress and therapeutic implications","[{\"question\":\"Why is efficient delivery of CRISPR components a key hurdle for treating solid tumors?\",\"answer\":\"The document highlights that success depends on delivering CRISPR components efficiently into tumor cells and tissues. Delivery limitations restrict the full therapeutic potential of CRISPR technology.\"},{\"question\":\"How do lipid nanoparticles (LNPs) support CRISPR/Cas9 therapeutic delivery?\",\"answer\":\"LNPs can encapsulate the CRISPR/Cas9 system, enabling targeted delivery. They are described as biocompatible and tunable, helping improve delivery efficiency while mitigating off-target effects.\"},{\"question\":\"What preclinical outcomes are associated with LNP-mediated CRISPR delivery in solid tumors?\",\"answer\":\"Pre-clinical investigations reported efficacy of LNP-mediated CRISPR delivery, including disruption of oncogenic pathways and subsequent tumor regression.\"}]","Preclinical Advances in LNP-CRISPR Therapeutics for Solid Tumor Treatment - Review | PDF",1790047729,35,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/42d248ef0e68a74a6b9d343c238401cb.webp",983,1390,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c1b9967a50471edb798f803afbea2081.webp",982,1388,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7b78407dd1c540d5c0fbc54e3b3978d4.webp",981,1387,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/710344be6b1766ec63c05e48059c59f8.webp",980,1385]